XERS Xeris Pharma: Market Value

Xeris Biopharma (XERS) is developing a scalable production model where XeriJect costs have already been recouped and the manufacturing of agents is delegated to external contractors, generating steady royalties from industry behemoths. The company is increasing the sale of hormonal agents while reducing losses, with the indicator standing at 3.03. This price chart demonstrates the asset's market dynamics. Simultaneously, the business is implementing eco-friendly packaging methods and energy-saving measures for drug storage.

XERS Xeris Biopharma Holdings: Market Capitalization in the range 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for Xeris Biopharma (XERS)

- current price and projected stock value:

Stock Price xerispharma.com|XERS - Average Forecast Price

- company stock capitalization data:

Market Value Xeris Biopharma Holdings, Inc.|XERS - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Xeris Biopharma|XERS - Book Valuation of Business|Market Value to Book Value Ratio xerispharma.com|XERS - Company Total Asset Base

- debt and solvency information:

- business earnings and investment ratios data:

XERS - Net Profit|Expected Profit Xeris Biopharma|XERS - Price to Earnings Ratio|Forward P/E Multiple xerispharma.com|XERS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Xeris Biopharma|XERS - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Xeris Biopharma|XERS - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth xerispharma.com|XERS - Earnings per share growth this year|Expected earnings per share growth for next year Xeris Biopharma

- sales volume and revenue indicators:

XERS - Company Sales Revenue|Company Projected Revenue Xeris Biopharma Holdings|XERS - Price-to-Sales Ratio|Forward P/S Multiple Xeris Biopharma Holdings, Inc.|XERS - Revenue Dynamics YoY (Last Twelve Months)

Initial company analysis:Xeris Pharma XERS

A stable cash flow from the sale of endocrine drugs, including Gvoke, creates the foundation for the business valuation reflected in the market capitalization of Xeris Biopharma (XERS). This indicator is calculated as the product of the current market price and the total number of shares outstanding, allowing investors to assess the total capital volume and the company's compliance with strict criteria for inclusion in stock indices.

Competitors of Xeris Biopharma (XERS)